- Home
- DECK vs INCY Comparison
DECK vs INCY Comparison
Compare DECK & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DECK | INCY |
|---|---|---|
| Founded | 1973 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 17.0B |
| IPO Year | 1996 | 1994 |
Fundamental Metrics
Financial Performance| Metric | DECK | INCY |
|---|---|---|
| Price | $98.53 | $95.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 21 |
| Target Price | ★ $122.20 | $102.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 05-21-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | 6.04 | ★ 6.41 |
| Revenue | ★ $4,985,612,000.00 | $3,394,635,000.00 |
| Revenue This Year | $11.16 | $10.97 |
| Revenue Next Year | $7.00 | $10.48 |
| P/E Ratio | $16.28 | ★ $14.97 |
| Revenue Growth | ★ 16.28 | 13.67 |
| 52 Week Low | $78.91 | $53.56 |
| 52 Week High | $131.58 | $112.29 |
Technical Indicators
Market Signals| Indicator | DECK | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 41.37 | 53.57 |
| Support Level | $96.80 | $93.54 |
| Resistance Level | $106.62 | $108.79 |
| Average True Range (ATR) | 3.71 | 2.45 |
| MACD | -0.01 | 0.65 |
| Stochastic Oscillator | 38.79 | 98.24 |
Price Performance
Historical ComparisonAbout DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets a niche sandal brand called Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.